1. Pepys MB, Hawkins PN: Amyloidosis. In: Oxford Text Book of Medicine, 5th edition, edited by DA Warrell, TM Cox, JD Firth. Oxford University Press, 2010, pp. 1766-1779
2. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596, 2003
3. Westermark P et al: A primer of amyloid nomenclature. Amyloid 14:179-183, 2007
4. Kyle RA, Gertz MA: Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 32:45-59, 1995
5. Comenzo RL et al: The tropism of organ involvement in primary systemic amyloidosis: Contributions of Ig VL germ line gene use and clonal plasma cell burden. Blood 98:714-720, 2001
6. Lachmann HJ et al: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361-2371, 2007
7. Pithukpakorn M, Aksentijevich I, Toro JR: Autoinflammatory diseases: Clinical and dermatologic features, genetics, pathogenesis and therapy. Adv Dermatol 22:67-90, 2006
8. Goodman HJB et al: Localized amyloidosis: Clinical features and outcome in 235 cases. Hematologica 90(Suppl 1):203, 2005 [abstract]
9. Benson MD: Ostertag revisited: The inherited systemic amyloidoses without neuropathy. Amyloid 12:75-87, 2005
10. Kyle RA, Bayrd ED: Amyloidosis: Review of 236 cases. Medicine 54:271-299, 1975
11. Shah PL et al: The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 19:134-142, 2002
12. Yoshida A et al: Lichen amyloidosis induced on the upper back by long-term friction with a nylon towel. J Dermatol 36(1):56-59, 2009
13. Gertz MA et al: Amyloidosis. Best Pract Res Clin Haematol 18:709-727, 2005
14. Benson MD, Kincaid JC: The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411-423, 2007
16. Schremi S et al: Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol 20(2):152-160, 2010
17. Ahmad QM et al: Systemic amyloidosis presenting as mucocutaneous bullous lesions. Hematol Oncol Stem Cell Ther 2:418-421, 2009
18. Gillmore JD et al: Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 14:2639-2644, 1999
19. Rocha N et al: Cutaneous manifestations of familial amyloidotic polyneuropathy. J Eur Acad Dermatol Venereol 19:605-607, 2005
20. Schwendiman MN et al: Primary cutaneous nodular amyloidosis: Case report and review of the literature. Cutis 84:87-92, 2009
21. Bridoux F et al: Localized amyloidosis: Clinical features and outcome in 203 cases. Paper presented at: Xth International Symposium on Amyloid and Amyloidosis, 2004; Tours, France
22. Westermark P et al: Galectin 7-associated cutaneous amyloidosis. Amyloid 17(Suppl 1):71, 2010
23. Meijer JM et al: Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? Arthritis Rheum 58(7):1992-1999, 2008
24. Tidman MJ, Wells RS, MacDonald DM: Pachyonychia congenita with cutaneous amyloidosis and hyperpigmentation—A distinct variant. J Am Acad Dermatol 16:935-940, 1987
25. Gullu S et al: Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant pheochromocytoma and ganglioneuroma. J Endocrinol Invest 28:734-737, 2005
26. Rasi A, Khatami A, Javaheri SM: Macular amyloidosis: An assessment of prevalence, sex, and age. Int J Dermatol 43:898-899, 2004
27. Wang WJ et al: Clinical and histopathological characteristics of primary cutaneous amyloidosis in 794 Chinese patients. Zhonghua Yi Xue Za Zhi (Taipei) 64:101-107, 2001
28. Uenishi T et al: Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits. J Dermatol 37:475-479, 2010
29. Wang WJ et al: Anosacral cutaneous amyloidosis: A study of 10 Chinese cases. Br J Dermatol 143:1266-1269, 2000
30. Yumlu S et al: Localized insulin-derived amyloidosis in patients with diabetes mellitus: A case report. Hum Pathol 40:1655-1660, 2009
31. Lin MW et al: Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis. Eur J Hum Genet 18(1):26-32, 2010
32. Gertz MA et al: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 79:319-328, 2005
33. British Committee for Standards in Haematology Working Group; Bird J et al. Guidelines on the diagnosis and management of AL amyloidosis, February 2003. Br J Haematol 125:681-700, 2004
34. Katzmann JA et al: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51(5):878-881, 2005
35. Puchtler H, Sweat F, Levine M: On the binding of Congo red by amyloid. J Histochem Cytochem 10:355-364, 1962
36. Linke RP et al: Classification of amyloidosis: Misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 108(3):197-208, 2006
37. Vrana JA et al: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114:4957-4959, 2009
38. Lachmann HJ et al: Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346:1786-1791, 2002
39. Hawkins PN, Lavender JP, Pepys MB: Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508-513, 1990
40. Halwani O, Delgado DH: Cardiac amyloidosis: An approach to diagnosis and management. Expert Rev Cardiovasc Ther 8(7):1007-1013, 2010
41. Maceira AM et al: Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54, 2008
42. Palladini G et al: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858, 2006
43. Dispenzieri A et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757, 2004
44. Dubrey SW, Falk RH: Amyloid heart disease. Br J Hosp Med (Lond) 71(2):76-82, 2010
45. Gertz MA et al: Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 24:3132-3137, 2009
46. Sattianayagam P, Hawkins P, Gillmore J: Amyloid and the GI tract. Expert Rev Gastroenterol Hepatol 3:615-630, 2009
47. Simmons Z, Specht CS: The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis 11(3):145-157, 2010
48. Wechalekar AD, Hawkins PN, Gillmore JD: Perspectives in treatment of AL amyloidosis. Br J Haematol 140:365-377, 2008
49. Herlenius G et al: Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: Results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation 77:64-71, 2004
50. Gertz MA et al: Risk-adjusted manipulation of
melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Bone Marrow Transplant 34:1025-1031, 2004
53. Wechalekar AD et al: Efficacy of
bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Haematologica 93:295-298, 2008
54. Sanchorawala V et al: Long-term outcome of patients with AL amyloidosis treated with high-dose
melphalan and stem-cell transplantation.
Blood 110:3561-3563, 2007
55. Moreau P et al: Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 101:766-769, 1998
56. Lachmann HJ, Hawkins PN: Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther 11:212, 2009
57. Stangou AJ et al: Liver transplantation in ATTR Met30 and other variants: Time to shift the paradigm? In: Amyloid and Amyloidosis, edited by G Grateau, RA Kyle, M Skinner. Boca Raton, Florida: CRC Press, 2005, p. 306-308
58. Dember LM: Emerging treatment approaches for the systemic amyloidoses. Kidney Int 68:1377-1390, 2005
59. Gillmore JD et al: Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 148(5):760-767, 2010
60. Clos AL et al: Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. Exp Dermatol 19(10):904-911, 2010
61. Pandhi R, Kaur I, Kumar B: Lack of effect of dimethylsulphoxide in cutaneous amyloidosis. J Dermatol Treat 13:11-14, 2002
62. Tran D, Kwok YK, Goh CL: A retrospective review of PUVA therapy at the National Skin Centre of Singapore. Photodermatol Photoimmunol Photomed 17:164-167, 2001
63. Castanedo-Cazares JP, Lepe V, Moncada B: Lichen amyloidosis improved by 0.1% topical
tacrolimus.
Dermatology 205:420-421, 2002
64. Grimmer J et al: Successful treatment of lichen amyloidosis with combined bath PUVA photochemotherapy and oral
acitretin.
Clin Exp Dermatol 32(1):39-42, 2006